Follicum announced that the company has successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005. The company expects to be ready for the start of the clinical study in patients with hairloss (alopecia) in early 2020. Preparations for the clinical trial are ongoing and the completed toxicology studies mark the achievement of an important milestone. Follicum has previously conducted several extensive toxicology studies with FOL-005 in which the substance was injected subcutaneously. The new results clearly indicate that the topical formulation is completely safe to use for patients. The results will be included in the application to the German Federal Institute for Drugs and Medical Devices (BfArM) for starting the clinical trial. Other preparations also proceed according to plan and Follicum expects to begin the upcoming clinical trial in early 2020.